费城住院患者芬太尼筛查阳性尿液中赛拉嗪高 prevalence
该研究开发了LC-MS/MS法检测尿液中赛拉嗪,并回顾性分析81例芬太尼免疫筛查阳性尿液,发现63例(78%)赛拉嗪阳性(>10 ng/ml)。提示住院患者中赛拉嗪暴露普遍,可能影响阿片类成瘾治疗管理。
要点
- 芬太尼筛查阳性尿液中赛拉嗪阳性率达78%。
- LC-MS/MS法检测赛拉嗪线性范围0-500 ng/ml,检出限10 ng/ml。
- 赛拉嗪暴露信息可能有助于指导阿片类成瘾患者管理。
核心结论
- 芬太尼筛查阳性尿液中赛拉嗪阳性率为78%(63/81)。
研究设计与样本
- 开发LC-MS/MS法检测尿液中赛拉嗪,并检测81例芬太尼免疫筛查阳性尿液样本。
主要发现
- 81例芬太尼筛查阳性尿液中63例(78%)赛拉嗪阳性(>10 ng/ml)。
- 校准曲线线性范围0-500 ng/ml,r>0.99。
- 批间CV为5.2%(18 ng/ml)和6.6%(95 ng/ml)。
- 检出限设为10 ng/ml(CV=15%)。
关键数值与推荐
- 赛拉嗪LC-MS/MS监测离子对为221>164(定量)和221>90(定性),内标d5-去甲芬太尼监测238>84。
- 色谱柱为Phenomenex Kinetix C18(100 A, 5 µm, 50 × 4.6 mm),柱温40 °C。
- 流动相A为0.1%甲酸水,B为0.1%甲酸甲醇,流速0.5 ml/min。
- 赛拉嗪和内标保留时间均为3.9 min。
临床怎么用
- 对芬太尼筛查阳性尿液可考虑用LC-MS/MS检测赛拉嗪以评估暴露。
- 赛拉嗪暴露信息可能辅助阿片类成瘾患者的临床管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Xylazine is an α-2 adrenoreceptor agonist used as a sedative/analgesic in veterinary medicine. Xylazine is known to be present within the street supply of opiates in urban Philadelphia. Medical staff at our hospital asked if we could test for xylazine in fentanyl screen-positive urine samples. We developed an LC-MS/MS assay for this purpose, and determined prevalence of xylazine among fentanyl screen-positive urine samples at our hospital. METHODS: The LC-MS/MS assay utilized d5-norfentanyl as internal standard (IS). One hundred microliter samples were extracted with 200 µl of MeOH/IS. LC was performed using a Phenomenex Kinetix C18 column (100 A, 5 µm, 50 × 4.6 mm) at 40 °C. Time-variable mobile phases (A = H2O, 0.1% formic acid; B = MeOH, 0.1% formic acid) were used at a fixed flow rate of 0.5 ml/min. MS/MS used positive electrospray ionization, monitoring m/z transitions of 221 > 164 for xylazine (primary), 221 > 90 for xylazine (qualifier), and 238 > 84 for d5-norfentanyl (IS). Retention time was 3.9 min for both xylazine and IS. RESULTS: Calibration curve was linear (0-500 ng/ml; r > 0.99). Inter-assay CVs (n = 20) were 5.2% (18 ng/ml) and 6.6% (95 ng/ml). Lower limit of detection was set at 10 ng/ml (CV = 15%). Among 81 urine samples that were screen-positive for fentanyl (Ark Diagnostics immunoassay), 63 (78%) were positive for xylazine (>10 ng/ml). CONCLUSIONS: By LC-MS/MS, there was high prevalence (78%) of xylazine in fentanyl screen-positive urine samples submitted to the laboratory. Because α-2 adrenoreceptor agonists may be used in treatment of opioid addiction, knowledge of xylazine exposure may be clinically useful to guide patient management.
引用
- Korn WR, Stone MD, Haviland KL, et al. High prevalence of xylazine among fentanyl screen-positive urines from hospitalized patients, Philadelphia, 2021. Clin Chim Acta. 2021. PMID: 34265257. doi:10.1016/j.cca.2021.07.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。